In the same study, it has been demonstrated that AVE1642 is able to downregulate Akt phosphorylation, and this effect was increased when AVE1642 was combined with gefitinib (EGFR inhibitor) or rapamycin (mTOR inhibitor)[88], supporting the efficacy of combined treatments in HCC. Here, MTOR is linked to hepatocellular carcinoma.